Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Munir, T (author)

Moreno, C (author)

Owen, C (author)

show more...

Follows, G (author)

Benjamini, O (author)

Janssens, A (author)

Levin, MD (author)

Osterborg, A (author)

Karolinska Institutet

Robak, T (author)

Simkovic, M (author)

Stevens, D (author)

Voloshin, S (author)

Vorobyev, V (author)

Yagci, M (author)

Ysebaert, L (author)

Qi, KQ (author)

Qi, QY (author)

Parisi, L (author)

Srinivasan, S (author)

Schuier, N (author)

Baeten, K (author)

Howes, A (author)

Caces, DB (author)

Niemann, CU (author)

Kater, AP (author)

show less...

 (creator_code:org_t)

2023

2023

English.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 41:21, s. 3689-

Related links:

http://kipublication...

show more...

https://doi.org/10.1...

show less...

• Journal article (peer-reviewed)